Chronic Myeloid Leukemia
Mostrando 1-12 de 221 artigos, teses e dissertações.
-
1. Chronic myeloid leukemia developing in treated acute promyelocytic leukemia
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
2. Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
ABSTRACT Introduction: Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success. Treatment discontinuation should not be proposed to the CML patient if minimum conditions are not met. In Brazil
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
3. Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
ABSTRACT This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and fr
Hematol., Transfus. Cell Ther.. Publicado em: 2021-06
-
4. Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management
ABSTRACT Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease that affects mainly adults between 50 and 55 years. In Brazil, information from the Sistema Único de Saúde (SUS) Outpatient Information System indicates that 12,531 patients had the Autorização de Procedimento Ambulatorial (APAC) approved for the CML treatment in 2017.
Hematol., Transfus. Cell Ther.. Publicado em: 2021-03
-
5. Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report
RESUMO Mimosa caesalpiniifolia Benth. (Fabaceae) é uma árvore nativa das florestas tropicais secas do Nordeste do Brasil e pode ser explorada para fins madeireiros e reflorestamento. Este estudo avaliou a qualidade fisiológica de sementes e a diversidade genética de uma população cultivada de M. caesalpiniifolia, tendo como base de sustentação o pote
Hematol., Transfus. Cell Ther.. Publicado em: 2020-10
-
6. Pesquisa em doenças inflamatórias intestinais no Brasil: um passo à frente rumo ao cuidado dos pacientes
Maytenus distichophylla is a medicinal species used in Northeast of Brazil. The hexane (HE), chloroform (CE), ethyl acetate (EAE) and methanol (ME) extracts and compounds from its roots were evaluated for their protective activity against Staphylococcus aureus and Candida albicans. The cytotoxicity for chronic myeloid leukemia (K562), acute monocytic leukemi
Arq. Gastroenterol.. Publicado em: 2020-09
-
7. CONSTITUENTS FROM ROOTS OF Maytenus distichophylla, ANTIMICROBIAL ACTIVITY AND TOXICITY FOR CELLS AND Caenorhabditis elegans
Maytenus distichophylla is a medicinal species used in Northeast of Brazil. The hexane (HE), chloroform (CE), ethyl acetate (EAE) and methanol (ME) extracts and compounds from its roots were evaluated for their protective activity against Staphylococcus aureus and Candida albicans. The cytotoxicity for chronic myeloid leukemia (K562), acute monocytic leukemi
Quím. Nova. Publicado em: 2020-09
-
8. Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
Abstract Introduction Hematologists deal every day with high mortality rates of acute leukemia patients. Many times these patients need Intensive Care Unit (ICU) support and some general ICU teams believe that these patients have a much greater chance of dying than patients with other pathologies. In Brazil, data related to mortality rates and ICUs for acut
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
9. A case of neurocognitive deficit strongly related to dasatinib therapy
Abstract Introduction Hematologists deal every day with high mortality rates of acute leukemia patients. Many times these patients need Intensive Care Unit (ICU) support and some general ICU teams believe that these patients have a much greater chance of dying than patients with other pathologies. In Brazil, data related to mortality rates and ICUs for acut
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
10. A case of multiple myeloma and synchronous liposarcoma
Abstract Introduction Hematologists deal every day with high mortality rates of acute leukemia patients. Many times these patients need Intensive Care Unit (ICU) support and some general ICU teams believe that these patients have a much greater chance of dying than patients with other pathologies. In Brazil, data related to mortality rates and ICUs for acut
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
11. Predictors of mortality among patients with acute leukemias admitted to an intensive care unit specialized in patients with hematological disease at a Brazilian hospital
Abstract Introduction Hematologists deal every day with high mortality rates of acute leukemia patients. Many times these patients need Intensive Care Unit (ICU) support and some general ICU teams believe that these patients have a much greater chance of dying than patients with other pathologies. In Brazil, data related to mortality rates and ICUs for acut
Hematol., Transfus. Cell Ther.. Publicado em: 2020-03
-
12. Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
ABSTRACT Introduction: The incidence of grade 3-4 anemia was reported to be 3% with imatinib therapy for newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). However, there are few data regarding the causes and the development of anemia after long-term treatment. This study aimed to evaluate the incidence of anemia after at least two ye
Hematol., Transfus. Cell Ther.. Publicado em: 25/11/2019